UGT1A polymorphisms as genetic biomarkers for hepatocellular carcinoma risk in Caucasian population

Elena De Mattia, Erika Cecchin, Jerry Polesel, Francesco Lupo, Claudio Tiribelli, Marina Crovatto, Angela Buonadonna, Giuseppe Toffoli

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Background & Aims: The definition of new biomarkers of hepatocellular carcinoma (HCC) risk, especially in high-risk HBV/HCV-positive population, is urgently needed to improve HCC clinical management. This study focused on variants of UDP-glucuronosyltransferase 1A (UGT1A) enzymes that catalyse the reaction of glucuronidation, one of the most important chemical defence pathway of the body. The aim of this study was to elucidate the contribution of UGT1A polymorphisms in predicting HCC susceptibility in Caucasians. Methods: In this retrospective case-control analysis, 192 HCC liver transplanted patients represent the study group. Two age/sex-matched groups were used as control, one composed of 167 HBV- and/or HCV-infected individuals, and the other of 192 healthy subjects. All the cases were characterized for a panel of UGT1A1, UGT1A7 and UGT1A9 variants. The study end-point was the association between UGT1A markers and HCC onset. Results: UGT1A7*3 allele emerged as a protective marker for HCC development among both high-risk HBV/HCV-positive patients (OR=0.64, P=.0026), and healthy subjects (OR=0.47, P=.0051). UGT1A1*28 (OR=0.61, P=.0013) and UGT1A9*22 (OR=2.18, P=.0003) alleles were also associated to HCC occurrence, especially among healthy subjects. UGT1A haplotype, summarizing the UGT1A genetic alterations, confirmed the protective role against HCC development emerged for low-activity alleles. The observed associations could probably be linked to an increase of serum levels of health-beneficial molecules including free bilirubin. Conclusion: A predictive effect of UGT1A polymorphisms on HCC risk was identified. If confirmed, these findings could contribute to improve the HCC surveillance, treatment tailoring and patients care.

Original languageEnglish
Pages (from-to)1345-1353
Number of pages9
JournalLiver International
Volume37
Issue number9
DOIs
Publication statusPublished - Sep 1 2017

Fingerprint

Glucuronosyltransferase
Hepatocellular Carcinoma
Biomarkers
Population
Healthy Volunteers
Alleles
Bilirubin
Haplotypes
Health Status
Patient Care
Research Design

Keywords

  • bilirubin
  • cancer risk
  • hepatocellular carcinoma
  • polymorphisms
  • UGT1As

ASJC Scopus subject areas

  • Hepatology

Cite this

UGT1A polymorphisms as genetic biomarkers for hepatocellular carcinoma risk in Caucasian population. / De Mattia, Elena; Cecchin, Erika; Polesel, Jerry; Lupo, Francesco; Tiribelli, Claudio; Crovatto, Marina; Buonadonna, Angela; Toffoli, Giuseppe.

In: Liver International, Vol. 37, No. 9, 01.09.2017, p. 1345-1353.

Research output: Contribution to journalArticle

@article{3fed5df214954121b47a431fecd7da8d,
title = "UGT1A polymorphisms as genetic biomarkers for hepatocellular carcinoma risk in Caucasian population",
abstract = "Background & Aims: The definition of new biomarkers of hepatocellular carcinoma (HCC) risk, especially in high-risk HBV/HCV-positive population, is urgently needed to improve HCC clinical management. This study focused on variants of UDP-glucuronosyltransferase 1A (UGT1A) enzymes that catalyse the reaction of glucuronidation, one of the most important chemical defence pathway of the body. The aim of this study was to elucidate the contribution of UGT1A polymorphisms in predicting HCC susceptibility in Caucasians. Methods: In this retrospective case-control analysis, 192 HCC liver transplanted patients represent the study group. Two age/sex-matched groups were used as control, one composed of 167 HBV- and/or HCV-infected individuals, and the other of 192 healthy subjects. All the cases were characterized for a panel of UGT1A1, UGT1A7 and UGT1A9 variants. The study end-point was the association between UGT1A markers and HCC onset. Results: UGT1A7*3 allele emerged as a protective marker for HCC development among both high-risk HBV/HCV-positive patients (OR=0.64, P=.0026), and healthy subjects (OR=0.47, P=.0051). UGT1A1*28 (OR=0.61, P=.0013) and UGT1A9*22 (OR=2.18, P=.0003) alleles were also associated to HCC occurrence, especially among healthy subjects. UGT1A haplotype, summarizing the UGT1A genetic alterations, confirmed the protective role against HCC development emerged for low-activity alleles. The observed associations could probably be linked to an increase of serum levels of health-beneficial molecules including free bilirubin. Conclusion: A predictive effect of UGT1A polymorphisms on HCC risk was identified. If confirmed, these findings could contribute to improve the HCC surveillance, treatment tailoring and patients care.",
keywords = "bilirubin, cancer risk, hepatocellular carcinoma, polymorphisms, UGT1As",
author = "{De Mattia}, Elena and Erika Cecchin and Jerry Polesel and Francesco Lupo and Claudio Tiribelli and Marina Crovatto and Angela Buonadonna and Giuseppe Toffoli",
year = "2017",
month = "9",
day = "1",
doi = "10.1111/liv.13411",
language = "English",
volume = "37",
pages = "1345--1353",
journal = "Liver International",
issn = "1478-3223",
publisher = "Wiley-Blackwell Publishing Ltd",
number = "9",

}

TY - JOUR

T1 - UGT1A polymorphisms as genetic biomarkers for hepatocellular carcinoma risk in Caucasian population

AU - De Mattia, Elena

AU - Cecchin, Erika

AU - Polesel, Jerry

AU - Lupo, Francesco

AU - Tiribelli, Claudio

AU - Crovatto, Marina

AU - Buonadonna, Angela

AU - Toffoli, Giuseppe

PY - 2017/9/1

Y1 - 2017/9/1

N2 - Background & Aims: The definition of new biomarkers of hepatocellular carcinoma (HCC) risk, especially in high-risk HBV/HCV-positive population, is urgently needed to improve HCC clinical management. This study focused on variants of UDP-glucuronosyltransferase 1A (UGT1A) enzymes that catalyse the reaction of glucuronidation, one of the most important chemical defence pathway of the body. The aim of this study was to elucidate the contribution of UGT1A polymorphisms in predicting HCC susceptibility in Caucasians. Methods: In this retrospective case-control analysis, 192 HCC liver transplanted patients represent the study group. Two age/sex-matched groups were used as control, one composed of 167 HBV- and/or HCV-infected individuals, and the other of 192 healthy subjects. All the cases were characterized for a panel of UGT1A1, UGT1A7 and UGT1A9 variants. The study end-point was the association between UGT1A markers and HCC onset. Results: UGT1A7*3 allele emerged as a protective marker for HCC development among both high-risk HBV/HCV-positive patients (OR=0.64, P=.0026), and healthy subjects (OR=0.47, P=.0051). UGT1A1*28 (OR=0.61, P=.0013) and UGT1A9*22 (OR=2.18, P=.0003) alleles were also associated to HCC occurrence, especially among healthy subjects. UGT1A haplotype, summarizing the UGT1A genetic alterations, confirmed the protective role against HCC development emerged for low-activity alleles. The observed associations could probably be linked to an increase of serum levels of health-beneficial molecules including free bilirubin. Conclusion: A predictive effect of UGT1A polymorphisms on HCC risk was identified. If confirmed, these findings could contribute to improve the HCC surveillance, treatment tailoring and patients care.

AB - Background & Aims: The definition of new biomarkers of hepatocellular carcinoma (HCC) risk, especially in high-risk HBV/HCV-positive population, is urgently needed to improve HCC clinical management. This study focused on variants of UDP-glucuronosyltransferase 1A (UGT1A) enzymes that catalyse the reaction of glucuronidation, one of the most important chemical defence pathway of the body. The aim of this study was to elucidate the contribution of UGT1A polymorphisms in predicting HCC susceptibility in Caucasians. Methods: In this retrospective case-control analysis, 192 HCC liver transplanted patients represent the study group. Two age/sex-matched groups were used as control, one composed of 167 HBV- and/or HCV-infected individuals, and the other of 192 healthy subjects. All the cases were characterized for a panel of UGT1A1, UGT1A7 and UGT1A9 variants. The study end-point was the association between UGT1A markers and HCC onset. Results: UGT1A7*3 allele emerged as a protective marker for HCC development among both high-risk HBV/HCV-positive patients (OR=0.64, P=.0026), and healthy subjects (OR=0.47, P=.0051). UGT1A1*28 (OR=0.61, P=.0013) and UGT1A9*22 (OR=2.18, P=.0003) alleles were also associated to HCC occurrence, especially among healthy subjects. UGT1A haplotype, summarizing the UGT1A genetic alterations, confirmed the protective role against HCC development emerged for low-activity alleles. The observed associations could probably be linked to an increase of serum levels of health-beneficial molecules including free bilirubin. Conclusion: A predictive effect of UGT1A polymorphisms on HCC risk was identified. If confirmed, these findings could contribute to improve the HCC surveillance, treatment tailoring and patients care.

KW - bilirubin

KW - cancer risk

KW - hepatocellular carcinoma

KW - polymorphisms

KW - UGT1As

UR - http://www.scopus.com/inward/record.url?scp=85017500810&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85017500810&partnerID=8YFLogxK

U2 - 10.1111/liv.13411

DO - 10.1111/liv.13411

M3 - Article

VL - 37

SP - 1345

EP - 1353

JO - Liver International

JF - Liver International

SN - 1478-3223

IS - 9

ER -